← Eichor
Condition: Metastatic Thyroid Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Thyroid Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Phase N/A · 9 location(s) · Children's Hospital of Philadelphia · NCT05024929XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 · 2 location(s) · Jochen Lorch · NCT06959641Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT03099356Selective Neck Dissection Versus Modified Neck Dissection in PTC
Phase 3 · 1 location(s) · Fudan University · NCT06554652Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Phase 2 · 1 location(s) · National Institute of Diabetes and Digestive and Kidney Dise · NCT04927416Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT05668962Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359847A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Phase 1 · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT03647358Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377Oropharynx (OPX) Biomarker Trial
Phase N/A · 1 location(s) · Mayo Clinic · NCT06356272A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carc
Phase 3 · 35 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT06860971Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
NA · 1 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT06405217Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
Phase 4 · 2 location(s) · Rigel Pharmaceuticals · NCT07704658Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05989425Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC
NA · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06623578New MRI Biomarkers in Head and Neck Cancers
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT03483337The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surger
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06800768Lateral Cervical Node Dissection in Differentiated Thyroid Cancer.
NA · 1 location(s) · Centro de Excelencia en Enfermedades de Cabeza y Cuello · NCT06149637Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Adv
NA · 1 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT06431620Pharmaceutical Management in Targeted Radioligand Therapy
Phase N/A · 3 location(s) · Hospices Civils de Lyon · NCT07389512A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So
Phase 1 · 83 location(s) · Pfizer · NCT05538130Irreversible Electroporation for Recurrent or Metastatic Cervical Lymph Node Metastases From Thyroid Cancer: A Prospecti
NA · 3 location(s) · Tian'an Jiang · NCT07328243Integrated Cancer Repository for Cancer Research
Phase N/A · 42 location(s) · University of Nebraska · NCT02012699Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Diff
Phase N/A · 3 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05994365Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06923826MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC
Phase 2 · 1 location(s) · Fudan University · NCT07235566Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06970353
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.